Vaximm Appoints Sébastien Wieckowski, PhD, as Chief Scientific Officer to Advance Next-Generation Oral Immunotherapy Platform

Rhea-AI Summary

Vaximm, a subsidiary of OSR Holdings (NYSE:OSRH), appointed Sébastien Wieckowski, PhD as Chief Scientific Officer on Jan 16, 2026. The company said his multidisciplinary background in immunology and advanced data science will lead strategic enhancements to the oral T‑cell VXM platform and support advancing the lead candidate VXM01 into later clinical stages while pursuing new targets. The appointment is positioned to strengthen R&D, platform reproducibility, and data‑driven discovery for oncology and non‑oncology programs.

News Market Reaction

-4.43%

5 alerts

-4.43% News Effect

-3.7% Trough in 1 hr 2 min

-$889K Valuation Impact

$19M Market Cap

0.4x Rel. Volume

On the day this news was published, OSRH declined 4.43%, reflecting a moderate negative market reaction. Argus tracked a trough of -3.7% from its starting point during tracking. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $889K from the company's valuation, bringing the market cap to $19M at that time.

Data tracked by StockTitan Argus on the day of publication.

Market Reality Check

Price: $0.7472 Vol: Volume 1,192,676 vs 20-da...

low vol

$0.7472 Last Close

Volume Volume 1,192,676 vs 20-day average 2,814,640 (relative volume 0.42x) suggests subdued trading interest pre‑news. low

Technical Price 0.7818 is trading below 200-day MA at 0.92 and far under the 10.00 52-week high, despite being above the 0.453 52-week low.

Peers on Argus

OSRH was up 6.5% while key biotech peers were mixed: ADAP down 17.57%, PHGE down...

1 Down

OSRH was up 6.5% while key biotech peers were mixed: ADAP down 17.57%, PHGE down 1.88%, PHIO down 0.88%, and APLM up 1.56%. Scanner activity showed only IMRN moving, down 4.67% without news. This points to a stock-specific reaction to the leadership appointment rather than a sector-wide move.

Historical Context

5 past events · Latest: Jan 12 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 12	VXM01 license term sheet	Positive	+8.3%	Binding term sheet for global VXM01 license with large upfront and milestones.
Dec 19	Subsidiary acquisition approval	Positive	+13.7%	Woori IO shareholders approve share exchange, making it a wholly-owned subsidiary.
Dec 02	Term sheet update	Neutral	-1.6%	Non-binding VXM01 term sheet revised to shorten exclusivity with similar economics.
Dec 01	Conference presentation	Neutral	-4.3%	Announcement of corporate overview presentation at Emerging Growth Conference.
Nov 21	Initial VXM01 term sheet	Positive	+23.4%	Non-binding term sheet with BCM Europe for exclusive global VXM01 license.

Pattern Detected

Recent Vaximm/OSRH news tied to licensing and corporate actions has often seen positive price alignment, especially around VXM01 deal developments, with occasional sell-offs on neutral updates and conference appearances.

Recent Company History

Over the last few months, OSRH has highlighted Vaximm’s VXM01 platform and broader corporate restructuring. On Nov 21, 2025 (news_id 939699), a non-binding term sheet with BCM Europe for a potential VXM01 license, including $20M upfront and up to $815M in milestones, coincided with a 23.38% gain. Subsequent updates on the term sheet and a conference appearance saw modest declines. Woori IO’s share-exchange approval on Dec 19, 2025 brought a 13.65% rise. The Jan 12, 2026 binding term sheet with BCM Europe again produced an 8.26% gain. Today’s CSO appointment fits an ongoing narrative of advancing VXM01 and platform leadership.

Market Pulse Summary

This announcement reinforces Vaximm’s focus on its oral T‑cell immunotherapy platform by elevating a...

Analysis

This announcement reinforces Vaximm’s focus on its oral T‑cell immunotherapy platform by elevating a long‑time contributor to Chief Scientific Officer as VXM01 moves into later-stage clinical development. In recent months, OSRH has paired this platform story with licensing term sheets and corporate transactions, some of which led to sizable price moves. Investors may watch how the new CSO’s data-driven strategy supports upcoming VXM01 milestones, the evolution of OSRH’s broader healthcare portfolio, and how future clinical and partnering updates compare to prior VXM01-related agreements.

Key Terms

oral T-cell immunotherapies, oncology, cell-based immunity

3 terms

oral T-cell immunotherapies medical

"Vaximm AG, a subsidiary of OSR Holdings, Inc. and a pioneer in oral T-cell immunotherapies for cancer,"

Therapies taken by mouth that are designed to activate, train, or modify the body’s T cells — a type of immune cell that targets infected or abnormal cells — to fight disease. Like a pill that teaches the immune system’s soldiers how to recognize and attack a target, oral delivery can make treatment simpler, lower costs and improve patient adherence, which matters to investors because it can expand market size but also brings unique development and regulatory challenges.

oncology medical

"development of our lead candidate VXM01 in oncology" said Dr. Constance Höfer,"

Oncology is the branch of medicine focused on understanding, diagnosing, and treating cancer, including the development and testing of drugs, therapies, and screening methods. It matters to investors because advances, trial results, regulatory approvals, or setbacks in cancer research can dramatically change the value of companies and the size of potential markets—think of oncology news as weather reports that help investors steer financial decisions in a high-stakes field.

cell-based immunity medical

"bridge deep understanding of immunology, particularly cell-based immunity, with advanced data science"

Cell-based immunity is the part of the immune system where specialized white blood cells identify and destroy infected or abnormal cells rather than relying on antibodies. For investors, it matters because therapies or vaccines that harness these cells can offer durable protection or treat diseases where antibodies alone fall short; think of it as a targeted cleanup crew versus a neighborhood watch. Success or setbacks in this area can affect clinical outcomes, regulatory approval, and company value.

AI-generated analysis. Not financial advice.

BELLEVUE, Wash., Jan. 16, 2026 /PRNewswire/ -- Vaximm AG, a subsidiary of OSR Holdings, Inc. and a pioneer in oral T-cell immunotherapies for cancer, today announced the appointment of Sébastien Wieckowski, PhD, as Chief Scientific Officer (CSO). This appointment strategically strengthens Vaximm's leadership with deep, long-standing expertise in the company's core technology.

Dr. Wieckowski brings multidisciplinary experience spanning immunology and advanced data science, a profile uniquely poised to integrate reproducible analytical workflows and data-driven strategies to accelerate discovery and optimize platform performance.

"I am excited to welcome Sébastien as CSO," said Dr. Andreas Niethammer, CEO of Vaximm. "Having worked closely with him since 2016, I have witnessed firsthand his deep scientific and technical mastery of our oral vector technology. His contributions to the overall program have been substantial, characterized by a rare combination of strategic vision and pragmatic execution. As we advance into later-stage clinical trials and begin integrating new assets, Sébastien's expertise will be vital in ensuring our scientific framework continues to be robust and innovative."

The appointment comes at a pivotal time as Vaximm advances its lead candidate, VXM01, into further stages of clinical development while actively pursuing new targets. In his new role as CSO, Dr. Wieckowski will lead strategic enhancements to Vaximm's VXM platform to further strengthen and expand its capabilities.

"Sébastien Wieckowski has been a cornerstone of Vaximm's R&D strategy, playing a crucial role in the development of our lead candidate VXM01 in oncology" said Dr. Constance Höfer, Chief Scientific Officer of OSR Holdings. "His appointment ensures a rigorous, data-driven evolution of Vaximm's core platform, enabling expansion to target a broad spectrum of oncology and non-oncology indications, while strengthening both the scientific foundation and the commercial potential. This aligns with OSR Holdings' broader strategy of advancing platform-driven assets toward later-stage strategic partnerships."

"Having been part of Vaximm's journey for over a decade—from early academic testing to the industrialization of our core assets—I am honored to now serve as Chief Scientific Officer," said Sébastien Wieckowski. "Our mission is to bridge deep understanding of immunology, particularly cell-based immunity, with advanced data science to develop therapies with unprecedented precision, scalability, and scope. By embedding integrated, data-driven analytical frameworks into our R&D platform, we are advancing next generation programs at the cutting edge of biomedical research to deliver cost-effective, patient-centric therapies with transformative impact across a wide range of therapeutic areas where precise target engagement, combined with high safety and tolerability, is essential."

About Vaximm AG

Vaximm AG is a privately held Swiss-German biotechnology company and a subsidiary of OSR Holdings, Inc. (NASDAQ: OSRH). Vaximm's proprietary oral T-cell immunotherapy platform harnesses live, attenuated bacterial vectors to deliver tumor-associated antigens, inducing robust cellular immune responses. Lead candidate VXM01, targeting VEGFR-2, has demonstrated clinical activity and safety in multiple cancer indications.

About OSR Holdings, Inc.

OSR Holdings, Inc. (NASDAQ: OSRH) is a global healthcare holding company dedicated to advancing biomedical innovations in health and wellness. Through its subsidiaries, OSRH engages in immuno-oncology, regenerative biologics, and medical device technologies to improve global health outcomes. Learn more at www.OSR-Holdings.com. 

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, including statements regarding Vaximm's development plans, future collaborations, and potential therapeutic benefits. These statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially. Neither OSR Holdings nor Vaximm undertakes any obligation to update or revise these statements.

View original content to download multimedia:https://www.prnewswire.com/news-releases/vaximm-appoints-sebastien-wieckowski-phd-as-chief-scientific-officer-to-advance-next-generation-oral-immunotherapy-platform-302663458.html

SOURCE OSR Holdings

FAQ

Who is Sébastien Wieckowski and what role did he accept at Vaximm (NYSE:OSRH)?

Sébastien Wieckowski, PhD, was appointed Chief Scientific Officer to lead scientific and platform strategy at Vaximm.

How does the appointment of Sébastien Wieckowski affect Vaximm's VXM01 clinical program?

The appointment is intended to support advancement of VXM01 into later clinical stages through strategic enhancements to the VXM platform.

What expertise does the new Vaximm CSO bring to the company?

He brings multidisciplinary experience in immunology and advanced data science, aimed at embedding reproducible analytical workflows and data‑driven discovery.

When was the CSO appointment at Vaximm announced?

The appointment was announced on January 16, 2026.

Will Sébastien Wieckowski lead platform expansion beyond oncology at Vaximm (NYSE:OSRH)?

Yes. The company indicated he will help expand the VXM platform to target a broad spectrum of oncology and non‑oncology indications.

How does this leadership change align with OSR Holdings' strategy for platform assets?

The appointment is presented as aligning with OSR Holdings' strategy to advance platform‑driven assets toward later‑stage strategic partnerships.